Actelion to Present at the 29th annual J.P. Morgan Healthcare Conference
Actelion Ltd (SIX: ATLN) Actelion Ltd (SIX: ATLN) announced today that Jean-Paul Clozel, M.D., Chief Executive Officer of Actelion, will present at the upcoming J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at 10.30 a.m. Pacific time / 7.30 p.m. Swiss time at the Westin St. Francis Hotel in San Francisco, CA.
- (1888PressRelease) January 12, 2011 - During the presentation, Dr.Clozel will confirm fiscal year 2010 top-line guidance. Total net revenues are expected to have grown the low-double digit range (in local currencies). Non-GAAP EBIT is expected to be slightly below the guided range of 21 to 24 percent, with higher than expected legal costs being a key contributing factor.
Jean-Paul Clozel, M.D. and Chief Executive Officer of Actelion commented: "I am delighted that our product sales continue to grow at a rapid pace and that our clinical pipeline is advancing. Our PAH franchise is strengthening, with the ongoing launch of an i.v therapy and with two innovative agents in late-stage clinical development. Our global business base allows us to invest appropriately into future innovative growth drivers while maintaining our high level of profitability."
Actelion will provide an updated overview of the company's products and development programs during its presentation. Actelion has currently more than 10 projects in clinical development. The company expects to report the results of four Phase II and two Phase III programs during 2011.
Jean-Paul Clozel added: "In its twelve years of operation, Actelion has created a multitude of opportunities so that we are well positioned to fulfill our commitment to ongoing and significant value creation for shareholders, patients and employees alike. Going forward, we will continue to leverage our assets through further product acquisitions and individually tailored partnerships with companies that have the required capabilities to maximize the value for a number of our development projects."
The company will also reiterate its 2011 financial outlook, with product sales - in local currencies - expected to increase in the mid-single digit range, notwithstanding ongoing pricing pressures, thereby continuing Actelion's multi-year sales growth track record. Excluding contract revenues, 2011 Non-GAAP EBIT - also in local currencies - is expected to grow faster than product sales, also the result of the continued focus on controlling the cost base.
Jean-Paul Clozel commented: "Even though 2011 is likely to be a more challenging year financially, as a result of the continued pricing pressure which the entire pharmaceutical industry is facing, Actelion remains one of the best positioned biotechnology companies globally."
The presentation is available in pdf-format on www.actelion.com To access the live and subsequently archived webcast of the presentation, visit "Events" in the Investor Relations section of Actelion's Web site. An archived replay will be available for 3 months beginning 24 hours after the live presentation.
Actelion Ltd.
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug TracleerŪ, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension.
Actelion markets TracleerŪ through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 2,400 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMIŪ).
For further information please contact:
Roland Haefeli
Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam